Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females

<table>Comparative anti-HPV-16 and anti-HPV-18 titers measured in two assays for Cervarix and Gardasil [<a href="/journals/isrn/2011/457204/#B121">126</a>]. Immunogenicity comparisons between Cervarix and Gardasil  one month after 3rd dose (month 7) in 18–45-year-old women: ELISA versus cLIA measurement systems. ELISA: enzyme-linked immunosorbent assay in ELISA units/mL (EU/mL). cLIA: competitive Luminex immunoassay in milliMerck units/mL (mMerckU/mL). GMT means geometric mean titer.</table>

International Scholarly Research Notices

fig6

Figure 6

Figure 6: Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females 